Last 12 months
Inside the activity.
2 purchase rows · 11 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 3 |
| Dec 2025 | 0 | 2 |
| Jan 2026 | 0 | 1 |
| Feb 2026 | 0 | 1 |
| Mar 2026 | 1 | 1 |
| Apr 2026 | 0 | 1 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 2 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 1 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 05, 2026 Filed Jan 6, 2026 21:10 UTC |
Duker Jay S.Director · President and CEO
|
Exercise / conversionCommon Stock | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001630864-26-000002 · primarydocument.xml · nonDerivative · entry 3 Duker Jay S. · CIK 0001630864 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 81,518 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 05, 2026 Filed Jan 7, 2026 21:07 UTC |
Ribeiro RamiroChief Medical Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 29,250 | $0.00 Strike: $8.26 | $0.00 |
DisclosureSEC source: 0002013623-26-000004 · primarydocument.xml · derivative · entry 3 Ribeiro Ramiro · CIK 0002013623 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 87,750 Underlying: Common Stock · 29,250 shares Expires 2035-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option to purchase will vest and become exercisable as follows: 25% at January 3, 2026 and the remainder ratably, on a monthly basis, over the remaining three years. Read SEC document |
| January 05, 2026 Filed Jan 7, 2026 21:07 UTC |
Ribeiro RamiroChief Medical Officer
|
SaleCommon Stock | 42,544 | $17.10 | $727,319.46 |
DisclosureSEC source: 0002013623-26-000004 · primarydocument.xml · nonDerivative · entry 2 Ribeiro Ramiro · CIK 0002013623 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.68 to $17.51. The reporting person undertakes to provide EyePoint Inc., any security holder of EyePoint Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 05, 2026 Filed Jan 7, 2026 21:07 UTC |
Ribeiro RamiroChief Medical Officer
|
Exercise / conversionCommon Stock | 29,250 | $8.26 | $241,605.00 |
DisclosureSEC source: 0002013623-26-000004 · primarydocument.xml · nonDerivative · entry 1 Ribeiro Ramiro · CIK 0002013623 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 42,544 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 03, 2026 Filed Jan 6, 2026 21:47 UTC |
Ribeiro RamiroChief Medical Officer
|
Exercise / conversionRestricted Stock Units · Derivative | 19,667 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0002013623-26-000002 · primarydocument.xml · derivative · entry 5 Ribeiro Ramiro · CIK 0002013623 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,333 Underlying: Common Stock · 19,667 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The restricted stock units vest in three ratable annual installments beginning January 3, 2026. F4 · derivative.expiration_date: The restricted stock units vest in three ratable annual installments beginning January 3, 2026. Read SEC document |
| January 03, 2026 Filed Jan 6, 2026 21:47 UTC |
Ribeiro RamiroChief Medical Officer
|
Tax withholdingCommon Stock | 6,373 | $17.48 | $111,400.04 |
DisclosureSEC source: 0002013623-26-000002 · primarydocument.xml · nonDerivative · entry 2 Ribeiro Ramiro · CIK 0002013623 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,294 F1 · price: No shares were sold - these shares were withheld by the issuer to satisfy tax withholding requirements in connection with the Reporting Person's exercise of his withholding right following the vesting of the restricted stock units. Read SEC document |
| January 03, 2026 Filed Jan 6, 2026 21:47 UTC |
Ribeiro RamiroChief Medical Officer
|
Exercise / conversionCommon Stock | 19,667 | $0.00 | $0.00 |
DisclosureSEC source: 0002013623-26-000002 · primarydocument.xml · nonDerivative · entry 1 Ribeiro Ramiro · CIK 0002013623 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,667 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 03, 2026 Filed Jan 6, 2026 21:10 UTC |
Elston GeorgeChief Financial Officer
|
Exercise / conversionRestricted Stock Units · Derivative | 19,667 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001429932-26-000002 · primarydocument.xml · derivative · entry 8 Elston George · CIK 0001429932 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,333 Underlying: Common Stock · 19,667 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The restricted stock units vest in three ratable annual installments beginning January 3, 2026. F5 · derivative.expiration_date: The restricted stock units vest in three ratable annual installments beginning January 3, 2026. Read SEC document |
| January 03, 2026 Filed Jan 6, 2026 21:10 UTC |
Elston GeorgeChief Financial Officer
|
Tax withholdingCommon Stock | 6,324 | $17.48 | $110,543.52 |
DisclosureSEC source: 0001429932-26-000002 · primarydocument.xml · nonDerivative · entry 2 Elston George · CIK 0001429932 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,457 F1 · price: No shares were sold - these shares were withheld by the issuer to satisfy tax withholding requirements in connection with the Reporting Person's exercise of his withholding right following the vesting of the restricted stock units. Read SEC document |
| January 03, 2026 Filed Jan 6, 2026 21:10 UTC |
Elston GeorgeChief Financial Officer
|
Exercise / conversionCommon Stock | 19,667 | $0.00 | $0.00 |
DisclosureSEC source: 0001429932-26-000002 · primarydocument.xml · nonDerivative · entry 1 Elston George · CIK 0001429932 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 76,781 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 03, 2026 Filed Jan 6, 2026 21:10 UTC |
Duker Jay S.Director · President and CEO
|
Exercise / conversionRestricted Stock Units · Derivative | 65,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001630864-26-000002 · primarydocument.xml · derivative · entry 8 Duker Jay S. · CIK 0001630864 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 130,000 Underlying: Common Stock · 65,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The restricted stock units vest in three ratable annual installments beginning January 3, 2026. F5 · derivative.expiration_date: The restricted stock units vest in three ratable annual installments beginning January 3, 2026. Read SEC document |
| January 03, 2026 Filed Jan 6, 2026 21:10 UTC |
Duker Jay S.Director · President and CEO
|
Tax withholdingCommon Stock | 23,447 | $17.48 | $409,853.56 |
DisclosureSEC source: 0001630864-26-000002 · primarydocument.xml · nonDerivative · entry 2 Duker Jay S. · CIK 0001630864 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,518 F1 · price: No shares were sold - these shares were withheld by the issuer to satisfy tax withholding requirements in connection with the Reporting Person's exercise of his withholding right following the vesting of the restricted stock units. Read SEC document |
| January 03, 2026 Filed Jan 6, 2026 21:10 UTC |
Duker Jay S.Director · President and CEO
|
Exercise / conversionCommon Stock | 65,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001630864-26-000002 · primarydocument.xml · nonDerivative · entry 1 Duker Jay S. · CIK 0001630864 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 74,965 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 21:06 UTC |
Hassan FredDirector
|
GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $17.48 | $0.00 |
DisclosureSEC source: 0001110744-26-000002 · primarydocument.xml · derivative · entry 1 Hassan Fred · CIK 0001110744 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2036-01-02 Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 16:05 UTC |
ANDO GORANDirector
|
GrantStock Option (Right to Buy) · Derivative | 41,500 | $0.00 Strike: $17.48 | $0.00 |
DisclosureSEC source: 0001110748-26-000002 · primarydocument.xml · derivative · entry 1 ANDO GORAN · CIK 0001110748 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,500 Underlying: Common Stock · 41,500 shares Expires 2036-01-02 Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 21:47 UTC |
Ribeiro RamiroChief Medical Officer
|
GrantStock Option (Right to Buy) · Derivative | 171,400 | $0.00 Strike: $17.48 | $0.00 |
DisclosureSEC source: 0002013623-26-000002 · primarydocument.xml · derivative · entry 4 Ribeiro Ramiro · CIK 0002013623 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 171,400 Underlying: Common Stock · 171,400 shares Expires 2036-01-02 F3 · derivative.exercise_date: The option to purchase will vest and become exercisable as follows: 25% at January 2, 2027 and the remainder ratably, on a monthly basis, over the remaining three years. Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 21:47 UTC |
Ribeiro RamiroChief Medical Officer
|
GrantRestricted Stock Units · Derivative | 85,700 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0002013623-26-000002 · primarydocument.xml · derivative · entry 3 Ribeiro Ramiro · CIK 0002013623 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 85,700 Underlying: Common Stock · 85,700 shares Expires not disclosed F2 · derivative.exercise_date: The restricted stock units will vest in three ratable annual installments beginning January 2, 2027. F2 · derivative.expiration_date: The restricted stock units will vest in three ratable annual installments beginning January 2, 2027. Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 16:06 UTC |
Landis John B.Director
|
GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $17.48 | $0.00 |
DisclosureSEC source: 0001477283-26-000002 · primarydocument.xml · derivative · entry 1 Landis John B. · CIK 0001477283 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2036-01-02 Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 21:07 UTC |
Lurker NancyDirector
|
GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $17.48 | $0.00 |
DisclosureSEC source: 0001450485-26-000003 · primarydocument.xml · derivative · entry 3 Lurker Nancy · CIK 0001450485 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2036-01-02 Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 21:10 UTC |
Elston GeorgeChief Financial Officer
|
GrantStock Option (Right to Buy) · Derivative | 126,000 | $0.00 Strike: $17.48 | $0.00 |
DisclosureSEC source: 0001429932-26-000002 · primarydocument.xml · derivative · entry 7 Elston George · CIK 0001429932 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 126,000 Underlying: Common Stock · 126,000 shares Expires 2036-01-02 F4 · derivative.exercise_date: The option to purchase will vest and become exercisable as follows: 25% at January 2, 2027 and the remainder ratably, on a monthly basis, over the remaining three years. Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 21:10 UTC |
Elston GeorgeChief Financial Officer
|
GrantRestricted Stock Units · Derivative | 63,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001429932-26-000002 · primarydocument.xml · derivative · entry 6 Elston George · CIK 0001429932 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 63,000 Underlying: Common Stock · 63,000 shares Expires not disclosed F3 · derivative.exercise_date: The restricted stock units will vest in three ratable annual installments beginning January 2, 2027. F3 · derivative.expiration_date: The restricted stock units will vest in three ratable annual installments beginning January 2, 2027. Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 16:05 UTC |
DICICCO WENDY FDirector
|
GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $17.48 | $0.00 |
DisclosureSEC source: 0001225165-26-000002 · primarydocument.xml · derivative · entry 1 DICICCO WENDY F · CIK 0001225165 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2036-01-02 Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 21:10 UTC |
Duker Jay S.Director · President and CEO
|
GrantStock Option (Right to Buy) · Derivative | 331,000 | $0.00 Strike: $17.48 | $0.00 |
DisclosureSEC source: 0001630864-26-000002 · primarydocument.xml · derivative · entry 7 Duker Jay S. · CIK 0001630864 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 331,000 Underlying: Common Stock · 331,000 shares Expires 2036-01-02 F4 · derivative.exercise_date: The option to purchase will vest and become exercisable as follows: 25% at January 2, 2027 and the remainder ratably, on a monthly basis, over the remaining three years. Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 21:10 UTC |
Duker Jay S.Director · President and CEO
|
GrantRestricted Stock Units · Derivative | 165,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001630864-26-000002 · primarydocument.xml · derivative · entry 6 Duker Jay S. · CIK 0001630864 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 165,000 Underlying: Common Stock · 165,000 shares Expires not disclosed F3 · derivative.exercise_date: The restricted stock units will vest in three ratable annual installments beginning January 2, 2027. F3 · derivative.expiration_date: The restricted stock units will vest in three ratable annual installments beginning January 2, 2027. Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 21:09 UTC |
Zaderej Karen L.Director
|
GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $17.48 | $0.00 |
DisclosureSEC source: 0001530968-26-000002 · primarydocument.xml · derivative · entry 1 Zaderej Karen L. · CIK 0001530968 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2036-01-02 Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 21:08 UTC |
Sanders Reginald J.Director
|
GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $17.48 | $0.00 |
DisclosureSEC source: 0002048275-26-000002 · primarydocument.xml · derivative · entry 1 Sanders Reginald J. · CIK 0002048275 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2036-01-02 Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 21:06 UTC |
Duty StuartDirector
|
GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $17.48 | $0.00 |
DisclosureSEC source: 0001970274-26-000002 · primarydocument.xml · derivative · entry 1 Duty Stuart · CIK 0001970274 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2036-01-02 Read SEC document |
| December 19, 2025 Filed Dec 23, 2025 21:03 UTC |
Elston GeorgeChief Financial Officer
|
GiftCommon Stock | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001429932-25-000007 · primarydocument.xml · nonDerivative · entry 2 Elston George · CIK 0001429932 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Indirect · By Family Trust Disclosed balance after: 25,000 F1 · kind: On December 19, 2025, the reporting person transferred owned shares of Common Stock of the Company to an irrevocable family trust of which JP Morgan Trust Company of Delaware is trustee and of which the reporting person's immediate family members are the sole beneficiaries (the "Family Trust"). F2 · ownership.nature: These securities are held in a trust for the benefit of the reporting person's children. JP Morgan Trust Company of Delaware is trustee of the Family Trust. The reporting person disclaims beneficial ownership of these securities and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| December 19, 2025 Filed Dec 23, 2025 21:03 UTC |
Elston GeorgeChief Financial Officer
|
GiftCommon Stock | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001429932-25-000007 · primarydocument.xml · nonDerivative · entry 1 Elston George · CIK 0001429932 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,114 F1 · kind: On December 19, 2025, the reporting person transferred owned shares of Common Stock of the Company to an irrevocable family trust of which JP Morgan Trust Company of Delaware is trustee and of which the reporting person's immediate family members are the sole beneficiaries (the "Family Trust"). Read SEC document |
| December 04, 2025 Filed Dec 5, 2025 21:06 UTC |
Lurker NancyDirector
|
SaleCommon Stock | 9,300 | $15.11 | $140,477.43 |
DisclosureSEC source: 0001450485-25-000009 · primarydocument.xml · nonDerivative · entry 1 Lurker Nancy · CIK 0001450485 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 206,547 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.95 to $15.36. The reporting person undertakes to provide EyePoint Pharmaceuticals Inc., any security holder of EyePoint Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. average price. Read SEC document |
| December 04, 2025 Filed Dec 8, 2025 21:03 UTC |
Cormorant Asset Management, LPFormer 10% Owner
Cormorant Global Healthcare Master Fund, LPFormer 10% Owner
Chen BihuaFormer 10% Owner
|
SaleCommon Stock | 60,000 | $15.70 | $942,240.00 |
DisclosureSEC source: 0000929638-25-004521 · form4.xml · nonDerivative · entry 1 Cormorant Asset Management, LP · CIK 0001583977 · Former 10% Owner Cormorant Global Healthcare Master Fund, LP · CIK 0001618442 · Former 10% Owner Chen Bihua · CIK 0001599214 · Former 10% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnotes Disclosed balance after: 8,265,000 F1 · price: The reported price represents the weighted average sale price of Common Stock (the "shares") sold in a series of open market transactions on the transaction date at prices ranging from $15.70 to $15.97 per share. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each price. All of the shares reported herein were sold by the Master Fund. F2 · ownership.nature: Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of Cormorant Global Healthcare Master Fund, LP (the "Master Fund"). Cormorant Global Healthcare GP, LLC ("GP LLC") serves as the general partner of the Master Fund. Bihua Chen serves as the managing member of Cormorant, GP LLC and the Master Fund. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose. Read SEC document |
| November 28, 2025 Filed Dec 1, 2025 21:09 UTC |
Lurker NancyDirector
|
SaleCommon Stock | 500 | $14.95 | $7,475.00 |
DisclosureSEC source: 0001450485-25-000007 · primarydocument.xml · nonDerivative · entry 2 Lurker Nancy · CIK 0001450485 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 215,847 F1 · price: The price reported in Column 4 is a weighted average price as these shares were sold in multiple transactions. The reporting person undertakes to provide EyePoint Pharmaceuticals Inc., any security holder of EyePoint Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 26, 2025 Filed Dec 1, 2025 21:09 UTC |
Lurker NancyDirector
|
SaleCommon Stock | 200 | $14.95 | $2,990.00 |
DisclosureSEC source: 0001450485-25-000007 · primarydocument.xml · nonDerivative · entry 1 Lurker Nancy · CIK 0001450485 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 216,347 F1 · price: The price reported in Column 4 is a weighted average price as these shares were sold in multiple transactions. The reporting person undertakes to provide EyePoint Pharmaceuticals Inc., any security holder of EyePoint Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 11, 2025 Filed Nov 12, 2025 21:03 UTC |
Ribeiro RamiroChief Medical Officer
|
SaleCommon Stock | 2,722 | $11.61 | $31,602.42 |
DisclosureSEC source: 0002013623-25-000005 · primarydocument.xml · nonDerivative · entry 1 Ribeiro Ramiro · CIK 0002013623 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · shares: Amount sold consists of 2,722 shares acquired on January 31, 2025, pursuant to EyePoint's 2019 Employee Stock Purchase Plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.30 to $11.75. The reporting person undertakes to provide EyePoint Pharmaceuticals Inc., any security holder of EyePoint Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 19, 2025 Filed Sep 22, 2025 20:11 UTC |
Elston GeorgeChief Financial Officer
|
GiftCommon Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001429932-25-000005 · primarydocument.xml · nonDerivative · entry 2 Elston George · CIK 0001429932 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Indirect · By Family Trust Disclosed balance after: 20,000 F1 · kind: On September 19, 2025, the reporting person transferred owned shares of Common Stock of the Company to an irrevocable family trust of which JP Morgan Trust Company of Delaware is trustee and of which the reporting person's immediate family members are the sole beneficiaries (the "Family Trust"). F3 · ownership.nature: These securities are held in a trust for the benefit of the reporting person's children. JP Morgan Trust Company of Delaware is trustee of the Family Trust. The reporting person disclaims beneficial ownership of these securities and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| September 19, 2025 Filed Sep 22, 2025 20:11 UTC |
Elston GeorgeChief Financial Officer
|
GiftCommon Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001429932-25-000005 · primarydocument.xml · nonDerivative · entry 1 Elston George · CIK 0001429932 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,114 F1 · kind: On September 19, 2025, the reporting person transferred owned shares of Common Stock of the Company to an irrevocable family trust of which JP Morgan Trust Company of Delaware is trustee and of which the reporting person's immediate family members are the sole beneficiaries (the "Family Trust"). F2 · balance_after: Includes 1,266 shares acquired on July 31, 2025, pursuant to EyePoint's 2019 Employee Stock Purchase Plan. Read SEC document |
| July 11, 2025 Filed Jul 11, 2025 20:07 UTC |
Zaderej Karen L.Director
|
Exercise / conversionRestricted Stock Units · Derivative | 2,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-25-005391 · primarydocument.xml · derivative · entry 2 Zaderej Karen L. · CIK 0001530968 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The restricted stock units vest in three equal annual installments beginning July 11, 2023. F1 · derivative.expiration_date: The restricted stock units vest in three equal annual installments beginning July 11, 2023. Read SEC document |
| July 11, 2025 Filed Jul 11, 2025 20:07 UTC |
Zaderej Karen L.Director
|
Exercise / conversionCommon Stock | 2,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-25-005391 · primarydocument.xml · nonDerivative · entry 1 Zaderej Karen L. · CIK 0001530968 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 10, 2025 Filed Jul 11, 2025 20:06 UTC |
Lurker NancyDirector
|
Exercise / conversionRestricted Stock Units · Derivative | 11,111 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-25-005390 · primarydocument.xml · derivative · entry 3 Lurker Nancy · CIK 0001450485 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,112 Underlying: Common Stock · 11,111 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The restricted stock units vests in three ratable annual installments beginning July 10, 2024. F2 · derivative.expiration_date: The restricted stock units vests in three ratable annual installments beginning July 10, 2024. Read SEC document |
| July 10, 2025 Filed Jul 11, 2025 20:06 UTC |
Lurker NancyDirector
|
Exercise / conversionCommon Stock | 11,111 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-25-005390 · primarydocument.xml · nonDerivative · entry 1 Lurker Nancy · CIK 0001450485 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 216,547 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 10, 2025 Filed Jul 11, 2025 20:06 UTC |
Duker Jay S.Director · President and CEO
|
Exercise / conversionRestricted Stock Units · Derivative | 16,667 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-25-005389 · primarydocument.xml · derivative · entry 4 Duker Jay S. · CIK 0001630864 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,667 Underlying: Common Stock · 16,667 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The restricted stock units vests in three ratable annual installments beginning July 10, 2024. F3 · derivative.expiration_date: The restricted stock units vests in three ratable annual installments beginning July 10, 2024. Read SEC document |
| July 10, 2025 Filed Jul 11, 2025 20:06 UTC |
Duker Jay S.Director · President and CEO
|
Tax withholdingCommon Stock | 7,688 | $11.06 | $85,029.28 |
DisclosureSEC source: 0001562180-25-005389 · primarydocument.xml · nonDerivative · entry 2 Duker Jay S. · CIK 0001630864 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,965 F1 · kind: No shares were sold - these shares were withheld by the issuer to satisfy tax withholding requirements in connection with the Reporting Person's exercise of his withholding right following the vesting of the restricted stock units. Read SEC document |
| July 10, 2025 Filed Jul 11, 2025 20:06 UTC |
Duker Jay S.Director · President and CEO
|
Exercise / conversionCommon Stock | 16,667 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-25-005389 · primarydocument.xml · nonDerivative · entry 1 Duker Jay S. · CIK 0001630864 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,653 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 02, 2025 Filed Jul 2, 2025 20:05 UTC |
Lurker NancyDirector
|
GiftStock Option (Right to Buy) · Derivative | 27,270 | $0.00 Strike: $20.40 | $0.00 |
DisclosureSEC source: 0001562180-25-005229 · primarydocument.xml · derivative · entry 10 Lurker Nancy · CIK 0001450485 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Family Trust Disclosed balance after: 27,270 Underlying: Common Stock · 27,270 shares Expires 2034-01-04 F1 · kind: On July 2, 2025, the reporting person transferred the vested portion of an option to purchase common stock, par value $0.001 per share ("Common Stock"), of EyePoint Pharmaceuticals, Inc. (the "Company"), to an irrevocable family trust of which the reporting person's spouse is trustee and of which the reporting person's immediate family members are the sole beneficiaries (the "Family Trust"). F7 · derivative.exercise_date: The option to purchase will vest and become exercisable over a four year period as follows: 25% at the one year anniversary of grant and then ratably over the remaining thirty-six months. At the time of the transfer, the portion of the option that was transferred to the Family Trust vested in full. The remaining portion of the option retained by the reporting person continues to vest on a monthly basis until January 5, 2028. F3 · ownership.nature: These securities are held in a trust for the benefit of the reporting person's children. The reporting person's spouse is trustee of the Family Trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| July 02, 2025 Filed Jul 2, 2025 20:05 UTC |
Lurker NancyDirector
|
GiftStock Option (Right to Buy) · Derivative | 27,270 | $0.00 Strike: $20.40 | $0.00 |
DisclosureSEC source: 0001562180-25-005229 · primarydocument.xml · derivative · entry 9 Lurker Nancy · CIK 0001450485 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,730 Underlying: Common Stock · 27,270 shares Expires 2034-01-04 F1 · kind: On July 2, 2025, the reporting person transferred the vested portion of an option to purchase common stock, par value $0.001 per share ("Common Stock"), of EyePoint Pharmaceuticals, Inc. (the "Company"), to an irrevocable family trust of which the reporting person's spouse is trustee and of which the reporting person's immediate family members are the sole beneficiaries (the "Family Trust"). F7 · derivative.exercise_date: The option to purchase will vest and become exercisable over a four year period as follows: 25% at the one year anniversary of grant and then ratably over the remaining thirty-six months. At the time of the transfer, the portion of the option that was transferred to the Family Trust vested in full. The remaining portion of the option retained by the reporting person continues to vest on a monthly basis until January 5, 2028. Read SEC document |
| July 02, 2025 Filed Jul 2, 2025 20:05 UTC |
Lurker NancyDirector
|
GiftStock Option (Right to Buy) · Derivative | 15,278 | $0.00 Strike: $9.11 | $0.00 |
DisclosureSEC source: 0001562180-25-005229 · primarydocument.xml · derivative · entry 8 Lurker Nancy · CIK 0001450485 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Family Trust Disclosed balance after: 31,944 Underlying: Common Stock · 15,278 shares Expires 2033-07-10 F1 · kind: On July 2, 2025, the reporting person transferred the vested portion of an option to purchase common stock, par value $0.001 per share ("Common Stock"), of EyePoint Pharmaceuticals, Inc. (the "Company"), to an irrevocable family trust of which the reporting person's spouse is trustee and of which the reporting person's immediate family members are the sole beneficiaries (the "Family Trust"). F6 · derivative.exercise_date: The option to purchase will vest and become exercisable over a four year period as follows: 25% at the one year anniversary of grant and then ratably over the remaining thirty-six months. At the time of the transfer, the portion of the option that was transferred to the Family Trust vested in full. The remaining portion of the option retained by the reporting person continues to vest on a monthly basis until July 10, 2027. F3 · ownership.nature: These securities are held in a trust for the benefit of the reporting person's children. The reporting person's spouse is trustee of the Family Trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| July 02, 2025 Filed Jul 2, 2025 20:05 UTC |
Lurker NancyDirector
|
GiftStock Option (Right to Buy) · Derivative | 15,278 | $0.00 Strike: $9.11 | $0.00 |
DisclosureSEC source: 0001562180-25-005229 · primarydocument.xml · derivative · entry 7 Lurker Nancy · CIK 0001450485 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,722 Underlying: Common Stock · 15,278 shares Expires 2033-07-10 F1 · kind: On July 2, 2025, the reporting person transferred the vested portion of an option to purchase common stock, par value $0.001 per share ("Common Stock"), of EyePoint Pharmaceuticals, Inc. (the "Company"), to an irrevocable family trust of which the reporting person's spouse is trustee and of which the reporting person's immediate family members are the sole beneficiaries (the "Family Trust"). F6 · derivative.exercise_date: The option to purchase will vest and become exercisable over a four year period as follows: 25% at the one year anniversary of grant and then ratably over the remaining thirty-six months. At the time of the transfer, the portion of the option that was transferred to the Family Trust vested in full. The remaining portion of the option retained by the reporting person continues to vest on a monthly basis until July 10, 2027. Read SEC document |
| July 02, 2025 Filed Jul 2, 2025 20:05 UTC |
Lurker NancyDirector
|
GiftStock Option (Right to Buy) · Derivative | 103,308 | $0.00 Strike: $3.26 | $0.00 |
DisclosureSEC source: 0001562180-25-005229 · primarydocument.xml · derivative · entry 6 Lurker Nancy · CIK 0001450485 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Family Trust Disclosed balance after: 272,358 Underlying: Common Stock · 103,308 shares Expires 2033-01-05 F1 · kind: On July 2, 2025, the reporting person transferred the vested portion of an option to purchase common stock, par value $0.001 per share ("Common Stock"), of EyePoint Pharmaceuticals, Inc. (the "Company"), to an irrevocable family trust of which the reporting person's spouse is trustee and of which the reporting person's immediate family members are the sole beneficiaries (the "Family Trust"). F5 · derivative.exercise_date: The option to purchase will vest and become exercisable over a four year period as follows: 25% at the one year anniversary of grant and then ratably over the remaining thirty-six months. At the time of the transfer, the portion of the option that was transferred to the Family Trust vested in full. The remaining portion of the option retained by the reporting person continues to vest on a monthly basis until January 6, 2027. F3 · ownership.nature: These securities are held in a trust for the benefit of the reporting person's children. The reporting person's spouse is trustee of the Family Trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| July 02, 2025 Filed Jul 2, 2025 20:05 UTC |
Lurker NancyDirector
|
GiftStock Option (Right to Buy) · Derivative | 103,308 | $0.00 Strike: $3.26 | $0.00 |
DisclosureSEC source: 0001562180-25-005229 · primarydocument.xml · derivative · entry 5 Lurker Nancy · CIK 0001450485 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 178,442 Underlying: Common Stock · 103,308 shares Expires 2033-01-05 F1 · kind: On July 2, 2025, the reporting person transferred the vested portion of an option to purchase common stock, par value $0.001 per share ("Common Stock"), of EyePoint Pharmaceuticals, Inc. (the "Company"), to an irrevocable family trust of which the reporting person's spouse is trustee and of which the reporting person's immediate family members are the sole beneficiaries (the "Family Trust"). F5 · derivative.exercise_date: The option to purchase will vest and become exercisable over a four year period as follows: 25% at the one year anniversary of grant and then ratably over the remaining thirty-six months. At the time of the transfer, the portion of the option that was transferred to the Family Trust vested in full. The remaining portion of the option retained by the reporting person continues to vest on a monthly basis until January 6, 2027. Read SEC document |
| July 02, 2025 Filed Jul 2, 2025 20:05 UTC |
Lurker NancyDirector
|
GiftStock Option (Right to Buy) · Derivative | 55,000 | $0.00 Strike: $10.13 | $0.00 |
DisclosureSEC source: 0001562180-25-005229 · primarydocument.xml · derivative · entry 4 Lurker Nancy · CIK 0001450485 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Family Trust Disclosed balance after: 200,000 Underlying: Common Stock · 55,000 shares Expires 2032-02-09 F1 · kind: On July 2, 2025, the reporting person transferred the vested portion of an option to purchase common stock, par value $0.001 per share ("Common Stock"), of EyePoint Pharmaceuticals, Inc. (the "Company"), to an irrevocable family trust of which the reporting person's spouse is trustee and of which the reporting person's immediate family members are the sole beneficiaries (the "Family Trust"). F4 · derivative.exercise_date: The option to purchase will vest and become exercisable over a four year period as follows: 25% at the one year anniversary of grant and then ratably over the remaining thirty-six months. At the time of the transfer, the portion of the option that was transferred to the Family Trust vested in full. The remaining portion of the option retained by the reporting person continues to vest on a monthly basis until February 9, 2026. F3 · ownership.nature: These securities are held in a trust for the benefit of the reporting person's children. The reporting person's spouse is trustee of the Family Trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.